Insights Center
ML Strategies Viewpoints
Search
Showing 65 - 72 of 500 results
ML Strategies Capitol Hill & Executive Branch Fall Preview
September 6, 2018
ML Strategies Health Care Preview – Week of September 4th
September 4, 2018|Blog
President Signs Legislation Reforming CFIUS & Export Controls
August 28, 2018|Alert
ML Strategies Weekly Health Care Preview – July 30, 2018
July 30, 2018|Blog
ML Strategies Weekly Health Care Preview – July 23, 2018
July 23, 2018|Blog
ML Strategies Health Care Preview – July 16, 2018
July 16, 2018|Blog
ML Strategies Weekly Health Care Preview – July 9, 2018
July 9, 2018|Blog
Massachusetts Legislature Strikes “Grand Bargain”
June 26, 2018|Alert
News & Press Releases
Former Senate Staffer Reveals How Congress Can Pass an Autonomous Vehicle Bill
November 19, 2019 | Legaltech News
In this Q&A published by Legaltech News, Vice President of ML Strategies Christian Fjeld—former lead Democratic Senate staffer tasked with shepherding the American Vision for Safer Transportation through Advancement of Revolutionary Technologies Act (AV START Act) through the Senate—discussed why Congress failed to pass the AV START Act, how autonomous vehicles’ complexity isn’t lawmakers’ largest hurdle, and why the data privacy debate may factor into the next autonomous vehicle bill.
Warren, Cassidy To FDA: How Will You Identify Device Remanufacturers?
October 23, 2019 | Inside Health Policy
An article published by Inside Health Policy quoted Aaron Josephson, Senior Director at ML Strategies, on Senators Elizabeth Warren (D-Mass.) and Bill Cassidy (R-La.) letter to U.S. Food and Drug Administration (FDA), requesting information about the FDA's upcoming guidance clarifying the distinction between remanufacturers and servicers.
To Pitch Pre-Cert to Congress, FDA Builds a Case First
September 26, 2019 | MedTechDive
MedTechDive reported that the U.S. Food and Drug Administration is not yet ready to go to Congress to seek new powers for its evolving precertification pilot for software, but it will need new authorities to determine how the experimental path fits into the current regulatory scheme. The article included commentary from Senior Director of ML Strategies Aaron Josephson and Mintz Associate Benjamin Zegarelli.